|
1
|
American Cancer Society. Colorectal cancer
facts and figures. http://www.cancer.org/research/cancerfactsstatistics/colorectal-cancer-facts-figures.
Last revised January 9, 2015. Accessed January 19, 2015
|
|
2
|
National Cancer Institute. Cancer stats
fact sheets/Colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html.
Accessed January 19, 2015
|
|
3
|
American Cancer Society. What are the key
statistics for pancreatic cancer. http://www.cancer.org/cancer/pancreatic-cancer/detailedguide/pancreatic-cancer-key-statistics.
Last revised: January 9, 2015. Accessed January 19, 2015
|
|
4
|
National Cancer Institute. Liver Cancer.
http://www.cancer.gov/cancertopics/types/liver.
Accessed January 19, 2015
|
|
5
|
National Cancer Institute. SEER Stat Fact
Sheets: Liver and Intrahepatic Bile Duct Cancer. http://seer.cancer.gov/statfacts/html/livibd.html.
Accessed January 19, 2015
|
|
6
|
Fidler IJ: Molecular biology of cancer:
invasion and metastasis. Cancer Principles and Practice of
Oncology. De Vita VT Jr, Hellman S and Rosenberg SA: 5th edition.
Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997
|
|
7
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar
|
|
9
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleiner DE and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43(Suppl): S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yurchenco PD and Schittny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590.
1990.PubMed/NCBI
|
|
12
|
Barsky SH, Siegal GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Invest. 49:140–147.
1983.PubMed/NCBI
|
|
13
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
15
|
Choong PF and Nadesapillai AP: Urokinase
plasminogen activator system: A multifunctional role in tumor
progression and metastasis. Clin Orthop Relat Res. 415:S46–S58.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
17
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang B, Tang F, Zhang B, Zhou Y, Feng J
and Rao Z: Matrix metalloproteinase-9 expression is closely related
to poor prognosis inpatients with colon cancer. World J Surg Oncol.
12:242014. View Article : Google Scholar
|
|
19
|
Harvey SR, Hurd TC, Markus G, Martinick
MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SNJ,
Driscoll DL, et al: Evaluation of urinary plasminogen activator,
its receptor, matrix metalloproteinase-9, and von Willebrand factor
in pancreatic cancer. Clin Cancer Res. 9:4935–4943. 2003.PubMed/NCBI
|
|
20
|
Bu W, Tang ZY, Ye SL, Liu KD, Huang XW and
Gao DM: The association of type IV collagenase with invasion and
metastasis of hepatocellular carcinoma. Zhonghua Xiachua Zazhi.
19:13–15. 1999.
|
|
21
|
Danø K, Andreasen PA, Grøndahl-Hansen J,
Kristensen P, Nielsen LS and Skriver L: Plasminogen activators,
tissue degradation, and cancer. Adv Cancer Res. 44:139–266. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Skelly MM, Troy A, Duffy MJ, Mulcahy HE,
Duggan C, Connell TG, O’Donoghue DP and Sheahan K: Urokinase-type
plasminogen activator in colorectal cancer: Relationship with
clinicopathological features and patient outcome. Clin Cancer Res.
3:1837–1840. 1997.
|
|
23
|
Xue A, Scarlett CJ, Jackson CJ, Allen BJ
and Smith RC: Prognostic significance of growth factors and the
urokinase-type plasminogen activator system in pancreatic ductal
adenocarcinoma. Pancreas. 36:160–167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY
and Tang HB: Invasion and metastasis of hepatocellular carcinoma in
relation to urokinase-type plasminogen activator, its receptor and
inhibitor. J Cancer Res Clin Oncol. 126:641–646. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. Orthomolecular Med. 7:17–23. 1992.
|
|
26
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: A review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Inhibition of invasion and MMPs by a nutrient
mixture in human cancer cell lines: A correlation study. Exp Oncol.
32:243–248. 2010.
|
|
29
|
Roomi MW, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vivo antitumor effect of ascorbic
acid, lysine, proline and green tea extract on human colon cancer
cell HCT-116 xenografts in nude mice: Evaluation of tumor growth
and immunohistochemistry. Oncol Rep. 13:421–425. 2005.PubMed/NCBI
|
|
30
|
Roomi MW, Roomi NW, Kalinovsky T,
Niedzwiecki A and Rath M: In vivo and In vitro effect of a nutrient
mixture on human hepatocarcinoma cell line SK-HEP-1. Exp Oncol.
32:84–91. 2010.PubMed/NCBI
|
|
31
|
Amin ARMR, Kucuk O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
33
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of the high-affinity lysine
binding sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochim Biophys Acta.
1596:182–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kemberling JK, Hampton JA, Keck RW, Gomez
MA and Selman SH: Inhibition of bladder tumor growth by the green
tea derivative epigallocatechin-3-gallate. J Urol. 170:773–776.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sato D and Matsushima M: Preventive
effects of urinary bladder tumors induced by
N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves.
Int J Urol. 10:160–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Valcic S, Timmermann BN, Alberts DS,
Wächter GA, Krutzsch M, Wymer J and Guillén JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mukhtar H and Ahmad N: Tea polyphenols:
Prevention of cancer and optimizing health. Am J Clin Nutr.
71(Suppl 6): 1698–1702; discussion 1703–1704. 2000.
|
|
38
|
Yang GY, Liao J, Kim K, Yurkow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimokawa R: Effect of (-)-epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hara Y: Green tea: Health Benefits and
Applications. Marcel Dekker; New York, Basel: 2001, View Article : Google Scholar
|
|
41
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effect of N-acetylcysteine on invasion and
MMP-9 production of T24 human bladder cancer cells. Anticancer Res.
21:213–219. 2001.PubMed/NCBI
|
|
42
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Flora S, D’Agostini F, Albini A and Fassina G: The
role of the thiol N-acetylcysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.
|
|
43
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effect of selenite on invasion of HT1080 tumor cells. J Biol Chem.
276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Naidu KA, Karl RC, Naidu KA and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: Association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: The utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: Effect on cell number, viability, and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH, et al: Differential
effects and transport kinetics of ascorbate derivatives in leukemic
cell lines. Anticancer Res. 18:2487–2493. 1998.PubMed/NCBI
|
|
48
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: Action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Núñez Martín C and Ortiz de Apodaca y Ruiz
A: Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of the consumption of food with an elevated
content of this vitamin. Nutr Hosp. 10:368–372. 1995.(In
Spanish).
|
|
50
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineoplastic activity of doxorubicin, cisplatin, and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: Role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Roomi MW, Ivanov V, Netke SP, Niedzwiecki
A and Rath M: Serum markers of the liver, heart, and kidney and
lipid profile and histopathology in ODS rats treated with nutrient
synergy. J AM Coll Nutr. 22:77abstract 86. 2003.
|
